[go: up one dir, main page]

ES2052495T3 - Terapia de fluidos con aniones l-lactato y/o piruvato. - Google Patents

Terapia de fluidos con aniones l-lactato y/o piruvato.

Info

Publication number
ES2052495T3
ES2052495T3 ES86309899T ES86309899T ES2052495T3 ES 2052495 T3 ES2052495 T3 ES 2052495T3 ES 86309899 T ES86309899 T ES 86309899T ES 86309899 T ES86309899 T ES 86309899T ES 2052495 T3 ES2052495 T3 ES 2052495T3
Authority
ES
Spain
Prior art keywords
lactate
fluid therapy
anions
pyruvate
pyruvate anions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES86309899T
Other languages
English (en)
Other versions
ES2052495T5 (es
Inventor
Richard L Veech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25205036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2052495(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of ES2052495T3 publication Critical patent/ES2052495T3/es
Application granted granted Critical
Publication of ES2052495T5 publication Critical patent/ES2052495T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PRESENTAN COMPUESTOS Y PROCESOS PARA LA REALIZACION DE UNA TERAPIA DE FLUIDO USANDO LOS ANIONES DE I - LACTATO, PIRUVATO, D BETAHIDROXIBUTIRATO, ACETOCETATO O MEZCLAS SIMILARES. EL D,L - LACTATO RACEMICO O LAS MEZCLAS DE ANIONES DE ACETATO DE LOS MISMOS QUE SON USADAS EN FLUIDOS AHORA SE CONOCE QUE NO SON DESEABLES, PORQUE CAUSAN EFECTOS TOXICOS Y ADVERSOS CUANDO SE ADMINISTRAN A MAMIFEROS.
ES86309899T 1985-12-18 1986-12-18 Terapia de fluidos con aniones l-lactato y/o piruvato. Expired - Lifetime ES2052495T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81091885A 1985-12-18 1985-12-18
US810918 1985-12-18

Publications (2)

Publication Number Publication Date
ES2052495T3 true ES2052495T3 (es) 1994-07-16
ES2052495T5 ES2052495T5 (es) 2005-07-16

Family

ID=25205036

Family Applications (1)

Application Number Title Priority Date Filing Date
ES86309899T Expired - Lifetime ES2052495T5 (es) 1985-12-18 1986-12-18 Terapia de fluidos con aniones l-lactato y/o piruvato.

Country Status (11)

Country Link
US (1) US5100677A (es)
EP (1) EP0249667B2 (es)
JP (1) JPS63502274A (es)
CN (1) CN86108978A (es)
AT (1) ATE80303T1 (es)
AU (4) AU6776887A (es)
DE (1) DE3686718T3 (es)
ES (1) ES2052495T5 (es)
GR (1) GR3006492T3 (es)
IL (1) IL81030A0 (es)
WO (1) WO1987003808A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020007A (en) * 1984-06-22 2000-02-01 Btg International Limited Fluid therapy with l-lactate and/or pyruvate anions
USRE38604E1 (en) * 1984-06-22 2004-09-28 Btg International Limited Fluid therapy with L-lactate and/or pyruvate anions
US5719119A (en) * 1985-12-18 1998-02-17 British Technology Group, Ltd. Parenteral nutrition therapy with amino acids
FR2619715A1 (fr) * 1987-08-25 1989-03-03 Bayle Francois Serum glucose polyionique iso-osmotique
US5310768A (en) * 1987-10-29 1994-05-10 Ab Erik Vinnars Method for improving the glutamine content in skeletal muscle and composition therefore
BE1001209A3 (fr) * 1987-11-19 1989-08-22 Solvay Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
US5292774A (en) * 1988-07-26 1994-03-08 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Substitution fluid preparation comprising 3-hydroxy-butyric acid (β-hydroxybutric acid) and its salts
US5112622A (en) * 1990-01-19 1992-05-12 Kopp Klaus F Intravenous solutions for influencing renal function and for maintenance therapy
EP0658353A1 (de) * 1993-11-19 1995-06-21 Bertold Dr. Reinhardt Pyruvathaltige CAPD- und Substitutionslösungen sowie pyruvathaltige Dialysierflüssigkeiten
BR9506021A (pt) * 1994-07-01 1997-10-14 Baxter Int Solução de diálise peritoneal e processo para corrigir a acidose metabólica
DE19549420A1 (de) * 1995-04-27 1997-09-18 Braun Melsungen Ag Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma
US6417231B1 (en) 1996-12-23 2002-07-09 Frank L. Greenway Method and composition for delivering therapeutically effective amounts of pyruvate to a mammal
US20090253781A1 (en) * 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
DE19859771C1 (de) * 1998-12-23 2000-08-24 Sueddeutsche Kalkstickstoff Wasserlösliche, stabile Brenztraubensäure(-salze)-enthaltende Formulierung
US8105258B2 (en) 1999-04-26 2012-01-31 Baxter International Inc. Citrate anticoagulation system for extracorporeal blood treatments
US7186420B2 (en) * 1999-04-26 2007-03-06 Edwards Lifesciences Corporation Multi-part substitution infusion fluids and matching anticoagulants
US6309673B1 (en) 1999-09-10 2001-10-30 Baxter International Inc. Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy
US6846842B2 (en) * 1999-10-07 2005-01-25 Beth Israel Deconess Medical Center, Inc. Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion
WO2002081020A2 (en) * 2001-04-04 2002-10-17 Critical Therapeutics, Inc. Method for preventing acute renal failure
WO2002096374A2 (en) * 2001-05-31 2002-12-05 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods comprising alpha-hydroxy acids or derivatives
US7122210B2 (en) 2002-01-11 2006-10-17 Baxter International Inc. Bicarbonate-based solutions for dialysis therapies
US20030232884A1 (en) * 2002-04-17 2003-12-18 Critical Therapeutics, Inc. New pharmaceutical formulation
US7445801B2 (en) 2002-06-07 2008-11-04 Baxter International Inc. Stable bicarbonate-based solution in a single container
IL151169A0 (en) * 2002-08-09 2003-04-10 Talgon Invest Ltd A peritoneal dialysis solution
US20040121982A1 (en) * 2002-12-20 2004-06-24 Leo Martis Biocompatible dialysis fluids containing icodextrins
EP1759695A1 (en) * 2003-05-01 2007-03-07 Innogene Kalbiotech Pte. Ltd. Lactate containing pharmaceutical composition and uses thereof
US7132221B2 (en) * 2003-09-12 2006-11-07 Headway Technologies, Inc. Method to print photoresist lines with negative sidewalls
ES2246690B1 (es) * 2004-03-30 2007-04-01 Jose Luis Pelluz Garcia Composicion de plasma sanguineo.
ES2246691B1 (es) * 2004-03-30 2007-04-01 Jose Luis Dieter De Shart, S.L. Composicion de acido l(+)-lactico de origen natural y organico.
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
US20050276868A1 (en) * 2004-06-10 2005-12-15 Bart Degreve Bicarbonate-based peritoneal dialysis solutions
EP1778213B1 (en) 2004-07-16 2017-04-05 BTG International Limited A method for the synthesis of oligomeric compounds
US7485743B2 (en) * 2004-07-20 2009-02-03 Btg International Limited Oligomeric ketone compounds
WO2006012490A2 (en) * 2004-07-23 2006-02-02 Ketocytonyx Inc. Ketogenic saccharides
WO2006034361A2 (en) * 2004-09-21 2006-03-30 Ketocytonyx Inc. Dopaminergic mimetics
US20070197645A1 (en) * 2004-09-21 2007-08-23 Martin Keith F Treatment of adhd
US7935070B2 (en) 2005-01-28 2011-05-03 Fresenius Medical Care North America Systems and methods for dextrose containing peritoneal dialysis (PD) solutions with neutral pH and reduced glucose degradation product
US20090285909A1 (en) * 2006-04-03 2009-11-19 Leverve Xavier M Lactate and Calcium Containing Pharmaceutical Composition and Uses Thereof
EP2146711A4 (en) 2007-04-12 2011-10-26 Univ Minnesota COMPOSITIONS FOR PROTECTION FROM ISCHEMIA / REPERFUSION AND APPLICATION PROCEDURES
US7754247B2 (en) * 2007-05-29 2010-07-13 University Of South Carolina Resuscitation fluid
US20120064178A1 (en) * 2010-09-13 2012-03-15 Carolyn Flora Anne Dean Cell-8 Solution
US9585810B2 (en) 2010-10-14 2017-03-07 Fresenius Medical Care Holdings, Inc. Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser
US8557301B2 (en) * 2011-07-01 2013-10-15 Drip Drop, Inc. Oral rehydration composition
US10292952B2 (en) * 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US10925843B2 (en) * 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
US20240325330A1 (en) * 2021-07-08 2024-10-03 Institut National de la Santé et de la Recherche Médicale New method to treat acidosis related diseases with acetoacetate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993750A (en) * 1974-12-20 1976-11-23 Research Corporation Aqueous hypertonic solution and compositions useful for preparation of same
US4308255A (en) * 1980-03-24 1981-12-29 Haemophor Corporation Balanced oncotic pressure fluid
ATE22655T1 (de) * 1982-11-10 1986-10-15 Laevosan Gmbh & Co Kg Infusionsloesungen zur herztherapie.
IT1214872B (it) † 1984-04-06 1990-01-18 Mariano Feriani Sacca contenente due o piu'sostanze per infusione ad uso medicale, poste in scomparti separati, comprendente mezzi atti a consentire la miscelazione di tali sostanze solo al momento dell'uso.
AU4634685A (en) * 1984-06-22 1986-01-24 R.L. Veech Electrolyte solutions and in vivo use thereof

Also Published As

Publication number Publication date
EP0249667A1 (en) 1987-12-23
AU6855890A (en) 1991-03-14
IL81030A0 (en) 1987-03-31
AU6066994A (en) 1994-06-23
DE3686718T2 (de) 1993-04-22
EP0249667B1 (en) 1992-09-09
EP0249667B2 (en) 2004-12-29
JPS63502274A (ja) 1988-09-01
ATE80303T1 (de) 1992-09-15
WO1987003808A1 (en) 1987-07-02
AU6776887A (en) 1987-07-15
AU2488097A (en) 1997-08-21
DE3686718D1 (de) 1992-10-15
DE3686718T3 (de) 2005-11-17
US5100677A (en) 1992-03-31
GR3006492T3 (es) 1993-06-21
CN86108978A (zh) 1987-11-04
ES2052495T5 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
ES2052495T3 (es) Terapia de fluidos con aniones l-lactato y/o piruvato.
DE19375061I2 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
DE3670398D1 (de) Quelle fluessiger metallionen.
ATE74001T1 (de) Transdermales therapeutisches system.
NL193440B (nl) Farmaceutisch preparaat met analgetische werking.
NL175882B (nl) Farmaceutisch preparaat, dat een verbinding met ontstekingtegengaande werking bevat.
ES2131122T3 (es) Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina.
NL172157C (nl) Preparaat met bloeddrukverlagende werking en de daarvoor geschikte werkzame verbindingen.
DK578887A (da) Antihypertensiva
NL192111B (nl) Geneesmiddelpreparaat met anti-inflammatoire werking.
ES2059869T3 (es) Preparado farmaceutico que contiene piroxicam para uso topico.
FI920428A0 (fi) Ett podofyllotoxinpreparat som innehaoller triglyserider.
ES2096050T3 (es) Derivados amidas del acido piridiltiazolidincarboxilico, su preparacion y sus usos.
ES2072869T3 (es) Uso de derivados de la 1,4-dihidropiridina en el tratamiento del alcoholismo.
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
ES2129401T3 (es) Uso de un compuesto terapeutico para el tratamiento de bronquitis.
SU601530A1 (ru) Вентил ционное устройство
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
NL6908529A (en) Benzomorphanes as analgesics and morphine- - autogenists
BE750985A (en) Benzomorphanes as analgesics and morphine- - autogenists
NL6908527A (en) Benzomorphanes as analgesics and morphine- - autogenists
NL6908528A (en) Benzomorphanes as analgesics and morphine- - autogenists
GT198172073A (es) Composiciones anti-inflamatorias.
DK479182A (da) Peptidpraeparat
GT198700072A (es) Procedimiento para preparar pirazolinas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 249667

Country of ref document: ES